Salloum Antoine, Habre Maya, Chebl Joanna Abi, Chebl Karen Abi, Atallah Carl, Medawar Georgio, Kourie Hampig R
Department of Internal Medicine, Roger Williams Medical Center, RI, USA.
Dermatologic SurgiCenter, Philadelphia, PA, USA.
Immunotherapy. 2022 Apr;14(6):489-503. doi: 10.2217/imt-2021-0244. Epub 2022 Mar 2.
This paper presents the reported dermatological adverse events (AEs) associated with approved combinations of immunotherapy with drugs of the same class, or in combination with targeted therapy or chemotherapy. PubMed was used as an electronic database, and a total of 29 articles were reviewed which reported dermatological AEs following combination therapies with nivolumab, ipilimumab, axitinib, pembrolizumab, lenvatinib, avelumab, atezolizumab, carboplatin, etoposide, paclitaxel, bevacizumab, pemetrexed, cisplatin and durvalumab. The dermatological AEs reported were mutually inclusive and the highest incidence of specific AEs was seen in the following combinations: rash in the nivolumab/ipilimumab and lenvatinib/pembrolizumab combinations, pruritus in the atezolizumab/nab-paclitaxel combination, dry skin and palmar-plantar erythrodysesthesia in the axitinib/pembrolizumab combination, and alopecia and severe skin reactions in the pembrolizumab/carboplatin/paclitaxel combination. Knowledge of such side effects is of benefit when choosing an optimal treatment regimen and should be integrated into the monitoring and follow-up phases of treatment.
本文介绍了与已获批的同类药物免疫疗法联合用药，或与靶向治疗或化疗联合用药相关的已报道的皮肤不良事件（AE）。使用PubMed作为电子数据库，共查阅了29篇文章，这些文章报道了与纳武单抗、伊匹木单抗、阿昔替尼、帕博利珠单抗、乐伐替尼、阿维鲁单抗、阿特珠单抗、卡铂、依托泊苷、紫杉醇、贝伐单抗、培美曲塞、顺铂和度伐鲁单抗联合治疗后的皮肤AE。所报道的皮肤AE相互包含，在以下联合用药中观察到特定AE的最高发生率：纳武单抗/伊匹木单抗和乐伐替尼/帕博利珠单抗联合用药出现皮疹，阿特珠单抗/白蛋白结合型紫杉醇联合用药出现瘙痒，阿昔替尼/帕博利珠单抗联合用药出现皮肤干燥和手足红斑感觉异常，帕博利珠单抗/卡铂/紫杉醇联合用药出现脱发和严重皮肤反应。了解此类副作用有助于选择最佳治疗方案，并且应纳入治疗的监测和随访阶段。
